CLDI Calidi Biotherapeutics, Inc.
No recent data for CLDI. Our end-of-day feed has carried no price for this security since 2026-09-02, and we found no SEC delisting or deregistration filing that would explain it — so this reflects the coverage of our data source. The security may still be trading, and quotes may be available elsewhere. Company filings and reported financials on this page are unaffected.
Updated
Healthcare · Biological Products, (No Diagnostic Substances)
Calidi Biotherapeutics, Inc. (CLDI) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $4 million. Price data for CLDI is unavailable — our feed has carried no quote since 2026-09-02.
Chart hidden: no price data for CLDI since 2026-09-02. Company filings and financials below are current.
Financials
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $-8.31 | 2026-08-13 |
| Q1 2026 | $-0.43 | 2026-05-14 |
| FY 2025 | $-5.95 | 2026-03-27 |
| Q3 2025 | $-6.40 | 2025-11-13 |
| Q2 2026 | $-66.47 | 2026-08-13 |
| Q1 2026 | $-2.21 | 2026-05-14 |
Biological Products, (No Diagnostic Substances) peers
CLDI vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated
| AMGN | Amgen | $240.1B | 27.47 | 6.30 | 23.0% | +0.31% |
| GILD | Gilead Sciences | $187.5B | -57.87 | 6.16 | -10.6% | +1.09% |
| MRNA | Moderna | $58.8B | -18.68 | — | — | -1.94% |
| RVMD | Revolution Medicines, Inc. | $45.2B | -25.55 | — | — | +0.76% |
| BIIB | Biogen | $33.1B | 24.16 | 3.34 | 13.8% | +0.78% |
| NBIX | Neurocrine Biosciences Inc | $16.1B | 22.81 | 4.77 | 20.9% | +0.33% |
| EXEL | Exelixis, Inc. | $14.7B | 17.03 | 6.02 | 35.3% | +1.00% |
| HALO | Halozyme Therapeutics, Inc. | $12.6B | 30.39 | 7.55 | 24.9% | +1.01% |
| TECH | Bio-Techne | $11.4B | 62.48 | 9.35 | 15.0% | +0.21% |
| KRYS | Krystal Biotech, Inc. | $11.0B | 45.52 | 24.95 | 54.8% | +0.58% |
| APGE | Apogee Therapeutics, Inc. | $10.2B | -34.57 | — | — | +0.04% |
| KYMR | Kymera Therapeutics, Inc. | $9.7B | -32.51 | — | — | -1.24% |
| RGEN | Repligen Corp | $9.6B | 230.53 | 12.20 | 5.3% | -1.87% |
| PCVX | Vaxcyte, Inc. | $9.1B | -8.56 | — | — | -0.62% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.